Comparative Pharmacology
Head-to-head clinical analysis: CONSTILAC versus CONSTULOSE.
Head-to-head clinical analysis: CONSTILAC versus CONSTULOSE.
CONSTILAC vs CONSTULOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Constilac (lactulose) is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids (e.g., lactic acid), which osmotically draw water into the bowel, producing a laxative effect. Additionally, in hepatic encephalopathy, the acidification of colonic contents traps ammonia (NH3) as ammonium (NH4+), reducing its absorption.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids, leading to an osmotic effect that draws water into the bowel, thereby softening stools and increasing bowel motility. In hepatic encephalopathy, lactulose acidifies the colonic environment, promoting the conversion of ammonia (NH3) to ammonium (NH4+), which is trapped and excreted in feces.
Oral, 15-45 mL (10-20 g lactulose) once daily, titrated to produce 2-3 soft stools daily; may be given as a single dose or divided twice daily. Onset of action 24-48 hours.
10-20 g (15-30 mL) orally once daily, increased to 30-45 g (45-60 mL) if needed; or 30-45 g (45-60 mL) orally every 6-8 hours for hepatic encephalopathy.
None Documented
None Documented
Not applicable due to negligible systemic absorption; lactulose acts locally in the colon.
Not applicable due to minimal systemic absorption; local action in colon. In cases of systemic absorption, half-life is not clinically relevant.
Primarily fecal as unchanged drug (systemic absorption negligible). Renal excretion accounts for <2% of any absorbed fraction. Biliary excretion is minimal.
Primarily fecal (unchanged); minimal systemic absorption (<3%), thus negligible renal excretion.
Category C
Category C
Osmotic Laxative
Osmotic Laxative